Amgen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +25

Amgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh ...

AI-generated analysis

📈 Amgen's updated analyst model raises fair value price target to US$388.03 from US$371.93, reflecting improved revenue growth assumptions and profit margin expectations.

🔍 Multiple analysts including UBS, Argus, TD Cowen, Scotiabank, and Oppenheimer raised targets to US$420-US$460 citing strong product portfolio performance and Q2 earnings beats.

💊 Wells Fargo and Piper Sandler increased targets to US$435 based on prescription data supporting higher long-term sales for Repatha and Lipfendra.

📉 HSBC downgraded Amgen to Hold and cut its target to US$425, noting that current stock price aligns closely with fair value with limited near-term upside.

⚠️ BMO Capital shifted to a neutral Market Perform rating at US$450 due to ongoing loss of exclusivity headwinds and uncertainty surrounding MariTide's competitive profile.

📊 Analyst models show revenue growth assumption shifting from 2.93% to 3.50% while net profit margin expectations rise from 24.84% to 25.15%.

🧬 Key investment themes include Amgen's late-stage pipeline in obesity, type 2 diabetes, cardiovascular disease, and oncology which could drive future high-margin launches.

🛡️ Strategic diversification efforts focus on biosimilars portfolio expansion, digital transformation initiatives, and reaching under-treated patient groups to stabilize revenue base.

⚖️ Primary risks identified include drug pricing pressure, biosimilar competition affecting products like Prolia, heavy R&D and manufacturing spend, and regulatory uncertainty.

Bullish Signals
  • Analysts including UBS, Argus, TD Cowen, Scotiabank, and Oppenheimer raised price targets to a US$420-US$460 range citing strong commercial execution and Q2 earnings beats.
  • Barclays and Bernstein highlighted broad product strength and higher guidance as support for confident forecasts of Amgen's execution across key franchises.
  • Wells Fargo and Piper Sandler lifted targets to US$435 based on external survey work and prescription data supporting higher long-term sales potential for Repatha and Lipfendra.
  • Updated analyst model increases fair value price target from US$371.93 to US$388.03, reflecting improved revenue growth assumptions shifting from 2.93% to 3.50%.
  • Net profit margin assumptions have been adjusted upward from 24.84% to 25.15%, indicating analysts expect stronger profitability in the coming periods.
Risk Factors
  • HSBC downgraded Amgen to Hold and cut its price target to US$425, stating that after strong execution the stock price more closely matches fair value with limited near-term upside.
  • BMO Capital shifted to a neutral Market Perform stance at US$450 citing ongoing loss of exclusivity headwinds and a need for more clarity on the competitive profile of MariTide.
  • Key risks include drug pricing pressure, biosimilar competition on products such as Prolia, heavy R&D and manufacturing spend, regulatory uncertainty, and demographic shifts.
Full Analysis
Amgen (AMGN) stock valuation has seen a modest lift as analyst models update fair value targets from US$371.93 to US$388.03, reflecting shifts in revenue growth assumptions from 2.93% to 3.50% and net profit margin expectations rising to 25.15%. This adjustment incorporates a slightly higher future P/E multiple of 25.1x and a discount rate increase to 7.96%, signaling evolving market pricing for the biopharmaceutical giant. Market sentiment remains mixed among major financial institutions, with several firms including UBS, Argus, TD Cowen, Scotiabank, Oppenheimer, Barclays, Bernstein, Wells Fargo, and Piper Sandler raising price targets to a US$420-US$460 range. These bullish moves cite strong commercial execution, recent Q2 earnings beats, higher guidance, and robust long-term sales potential for key cholesterol and cardiovascular franchises like Repatha and Lipfendra. Conversely, HSBC downgraded Amgen to Hold with a reduced target of US$425, while BMO Capital adopted a neutral Market Perform stance at US$450. These bearish adjustments highlight concerns over ongoing loss of exclusivity on existing products, competitive pressures from biosimilars, and the need for greater clarity on the sales trajectory of its pipeline candidate MariTide.